Brain Calcium Channels and Glioblastoma: New Ways to Tame a Deadly Brain Cancer
Official title: Brain Microenvironment Calcium Channels Modulate Glioblastoma
Funded at University of Virginia · NIH-11442852 · Data updated 2026-11-12
This grant studies how calcium channels in brain cells influence glioblastoma growth and whether blocking them can lead to new therapies for this very aggressive brain tumor.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project start | August 1, 2026 |
| Project end | July 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $523,232 |
| NIH project number | 1R01CA316617-01 |
| Project ID | NIH-11442852 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with glioblastoma or individuals at risk who could participate in future translational studies or trials derived from these findings.
✕Less likely to help
Patients whose tumors do not rely on Cav3.2-mediated microenvironment interactions might see no direct benefit.
What this research studies
Researchers at the University of Virginia will explore how calcium channels in both tumor cells and the surrounding brain environment affect glioblastoma progression. They will study the role of Cav3.2 in neurons and oligodendrocyte precursor cells, and how these channels influence signaling that helps or hinders tumor growth. The work uses cell cultures and animal models to uncover mechanisms and potential translational targets for therapy. If the findings translate to humans, this could guide the development of new treatments that disrupt tumor-supportive brain signals.
Why it matters
Potential benefit: Potentially leading to new therapies that slow or stop glioblastoma growth and improve survival and quality of life for patients.
How similar studies have gone: Preclinical studies have shown that targeting Cav3.2 in the brain microenvironment can influence tumor growth, suggesting translational potential, though human data are needed.
Where this research is happening
-
University of Virginia
Charlottesville, United States Active
Researchers
- Principal investigator: Abounader, Roger — University of Virginia
- Study coordinator: Abounader, Roger
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.